​

Roivant Sciences (ROIV) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

ROIV Stock Forecast

Roivant Sciences (ROIV) stock forecast, based on 14 Wall Street analysts, predicts a 12-month average price target of $25.75, with a high of $32.00 and a low of $20.00. This represents a 16.52% increase from the last price of $22.10.

$10 $15 $20 $25 $30 $35 High: $32 Avg: $25.75 Low: $20 Last Closed Price: $22.1

ROIV Stock Rating

Roivant Sciences stock's rating consensus is Buy, based on 14 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 13 Buy (92.86%), 1 Hold (7.14%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 14 0 1 13 Strong Sell Sell Hold Buy Strong Buy

ROIV Price Target Upside V Benchmarks

TypeNameUpside
StockRoivant Sciences16.52%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts277
Avg Price Target$29.00$24.71$24.71
Last Closing Price$22.10$22.10$22.10
Upside/Downside31.22%11.81%11.81%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Dec, 25291--12
Nov, 25381--12
Oct, 25381--12
Sep, 25371--11
Aug, 25371--11
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Dec 15, 2025David RisingerLeerink Partners$32.00$22.1044.80%44.80%
Dec 12, 2025H.C. Wainwright$26.00$21.4721.10%17.65%
Nov 14, 2025Yastin SunejaGuggenheim$25.00$20.5621.60%13.12%
Nov 11, 2025David RisingerLeerink Partners$29.00$21.1736.99%31.22%
Sep 18, 2025Jefferies$20.00$15.4729.28%-9.50%
Sep 18, 2025Guggenheim$21.00$15.2437.80%-4.98%
Sep 18, 2025H.C. Wainwright$20.00$15.2431.23%-9.50%
Oct 21, 2024David RisingerLeerink Partners$17.00$11.9242.62%-23.08%
Sep 19, 2024Corinne JenkinsGoldman Sachs$17.00$12.0640.96%-23.08%
Sep 11, 2024Chi FongBank of America Securities$12.50$12.460.32%-43.44%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Dec 15, 2025Leerink PartnersOutperformOutperformhold
Dec 12, 2025H.C. WainwrightBuyBuyhold
Nov 14, 2025GuggenheimBuyBuyhold
Nov 11, 2025Leerink PartnersOutperformOutperformhold
Oct 29, 2025CitigroupBuyBuyhold
Sep 18, 2025CitigroupNeutralNeutralhold
Sep 18, 2025JefferiesBuyBuyhold
Sep 18, 2025GuggenheimBuyBuyhold
Sep 18, 2025H.C. WainwrightBuyBuyhold
Sep 02, 2025CitigroupOverweightBuyinitialise

Financial Forecast

EPS Forecast

$-3 $-2 $-1 $0 $1 $2 $3 $4 $5 $6 Mar 23 Mar 24 Mar 24 Mar 25 Mar 26 Mar 27 Mar 28 Mar 29
Mar 23Mar 24Mar 25Mar 26Mar 27Mar 28Mar 29
Reported$-1.42$5.55-----
Avg Forecast$-1.59$5.22$-0.77$-1.09$-1.07$-0.47$0.20
High Forecast$-0.73$5.41$-0.72$-0.81$-0.82$-0.22$0.33
Low Forecast$-2.63$4.98$-0.81$-1.29$-1.39$-0.77$0.09
Surprise %-10.69%6.32%-----

Revenue Forecast

$0 $500M $1B $2B $2B $3B Mar 23 Mar 24 Mar 24 Mar 25 Mar 26 Mar 27 Mar 28 Mar 29
Mar 23Mar 24Mar 25Mar 26Mar 27Mar 28Mar 29
Reported$61.28M$124.80M-----
Avg Forecast$52.28M$181.74M$92.10M$34.74M$61.48M$762.32M$1.57B
High Forecast$78.79M$193.36M$139.48M$59.09M$92.67M$1.15B$2.37B
Low Forecast$30.60M$176.37M$56.33M$17.27M$35.98M$446.16M$920.09M
Surprise %17.22%-31.33%-----

Net Income Forecast

$-3B $-1B $300M $2B $3B $5B Mar 23 Mar 24 Mar 24 Mar 25 Mar 26 Mar 27 Mar 28 Mar 29
Mar 23Mar 24Mar 25Mar 26Mar 27Mar 28Mar 29
Reported$-1.01B$4.35B-----
Avg Forecast$-1.32B$4.35B$-605.08M$-804.05M$-911.26M$-387.83M$163.44M
High Forecast$-608.11M$4.50B$-596.22M$-672.44M$-682.96M$-178.73M$271.22M
Low Forecast$-2.19B$4.14B$-670.75M$-1.07B$-1.15B$-643.57M$75.32M
Surprise %-23.53%-0.07%-----

ROIV Forecast FAQ

Is Roivant Sciences stock a buy?

Roivant Sciences stock has a consensus rating of Buy, based on 14 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 13 Buy, 1 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Roivant Sciences is a favorable investment for most analysts.

What is Roivant Sciences's price target?

Roivant Sciences's price target, set by 14 Wall Street analysts, averages $25.75 over the next 12 months. The price target range spans from $20 at the low end to $32 at the high end, suggesting a potential 16.52% change from the previous closing price of $22.1.

How does Roivant Sciences stock forecast compare to its benchmarks?

Roivant Sciences's stock forecast shows a 16.52% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Roivant Sciences over the past three months?

  • December 2025: 16.67% Strong Buy, 75.00% Buy, 8.33% Hold, 0% Sell, 0% Strong Sell.
  • November 2025: 25.00% Strong Buy, 66.67% Buy, 8.33% Hold, 0% Sell, 0% Strong Sell.
  • October 2025: 25.00% Strong Buy, 66.67% Buy, 8.33% Hold, 0% Sell, 0% Strong Sell.

What is Roivant Sciences’s EPS forecast?

Roivant Sciences's average annual EPS forecast for its fiscal year ending in March 2025 is $-0.77, marking a -113.87% decrease from the reported $5.55 in 2024. Estimates for the following years are $-1.09 in 2026, $-1.07 in 2027, $-0.47 in 2028, and $0.2 in 2029.

What is Roivant Sciences’s revenue forecast?

Roivant Sciences's average annual revenue forecast for its fiscal year ending in March 2025 is $92.1M, reflecting a -26.20% decrease from the reported $124.8M in 2024. The forecast for 2026 is $34.74M, followed by $61.48M for 2027, $762.32M for 2028, and $1.57B for 2029.

What is Roivant Sciences’s net income forecast?

Roivant Sciences's net income forecast for the fiscal year ending in March 2025 stands at $-605M, representing a -113.91% decrease from the reported $4.35B in 2024. Projections indicate $-804M in 2026, $-911M in 2027, $-388M in 2028, and $163.44M in 2029.